Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model
1993; Springer Science+Business Media; Volume: 6; Issue: 4 Linguagem: Inglês
10.1007/bf00337106
ISSN1432-2277
AutoresJoan Torras, Joan R. Bordalba, Daniel Serón, Rosa Expósito Moliner, Marta Carrera, Joaquim Vallès, A. Martinez-Castelao, J Alsina, Josep M. Gri�o,
Tópico(s)Poisoning and overdose treatments
ResumoTransplant InternationalVolume 6, Issue 4 p. 236-238 Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model JOAN Torras, JOAN Torras Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, Spain Unitat de Recerca Experimental, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorJOAN R. Bordalba, JOAN R. Bordalba Department of Urology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, Spain Unitat de Recerca Experimental, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorDANIEL Seron, DANIEL Seron Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorROSA Moliner, ROSA Moliner Department of Biochemistry, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorMARTA Carrera, MARTA Carrera Department of Pathology, Hospital de Bellvitge, Feixa Llarga s/n. E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorJOAQUIM Valles, JOAQUIM Valles S. A. Lasa Laboratories, Laurea Miro s/n, Sant Felin de Llobregat, Barcelona, SpainSearch for more papers by this authorALBERT Martinez-Castelao, ALBERT Martinez-Castelao Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorJERONI Alsina, JERONI Alsina Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorJOSEP M. Grino, Corresponding Author JOSEP M. Grino Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, Spain*J. M. GrinoSearch for more papers by this author JOAN Torras, JOAN Torras Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, Spain Unitat de Recerca Experimental, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorJOAN R. Bordalba, JOAN R. Bordalba Department of Urology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, Spain Unitat de Recerca Experimental, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorDANIEL Seron, DANIEL Seron Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorROSA Moliner, ROSA Moliner Department of Biochemistry, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorMARTA Carrera, MARTA Carrera Department of Pathology, Hospital de Bellvitge, Feixa Llarga s/n. E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorJOAQUIM Valles, JOAQUIM Valles S. A. Lasa Laboratories, Laurea Miro s/n, Sant Felin de Llobregat, Barcelona, SpainSearch for more papers by this authorALBERT Martinez-Castelao, ALBERT Martinez-Castelao Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorJERONI Alsina, JERONI Alsina Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorJOSEP M. Grino, Corresponding Author JOSEP M. Grino Department of Nephrology, Hospital de Bellvitge, Feixa Llarga s/n, E-08097 L'Hospitalet de Llobregat, Barcelona, Spain*J. M. GrinoSearch for more papers by this author First published: July 1993 https://doi.org/10.1111/j.1432-2277.1993.tb00654.xCitations: 19AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Abstract Platelet activating factor is involved in warm ischemic damage. We studied the effect of the PAF receptor antagonist BN 52021 in an experimental model of 60 min of renal warm ischemia in which the left kidney was flushed with Euro-Collins solution and a right nephrectomy was performed. Eighty Wistar rats were divided into a sham-operated group, two control groups, and four study groups, according to the dosage and route of BN 52021 administration. BN 52021 was used in the flush solution at concentrations of 0.1 and 0.5 mg/;ml, or intravenously prior to ischemia at 5 and lOmg/kg body weight. Creatinine clearance per 100 g body weight, fractional sodium excretion, and conventional histology were studied. Rats that received BN 52021 intravenously showed a significantly higher creatinine clearance than controls. Intravenous BN 52021 produced a higher acceleration of renal function recovery at 10 mg/kg than at 5 mg/kg body weight. Conventional histology was better in animals that received BN 52021 at 10 mg/kg body weight than in controls. Addition of BN 52021 to Euro-Collins flushing solution showed no protective effect. We conclude that intravenous BN 52021 shows a renal protective effect against warm ischemia. References 1 Braquet P., Touqui L., Shen TY, Vargaftig BB (1987) Perspectives in platelet activating factor research. Pharmacol Rev 39, 97–145. CASPubMedWeb of Science®Google Scholar 2 Conte JV, Katz NM, Wallace RB, Foegh ML (1991) Long-term lung preservation with the PAF antagonist BN 52021. Transplantation 51, 1152–1156. 10.1097/00007890-199106000-00002 PubMedWeb of Science®Google Scholar 3 Droy-Lefaix MT, Drouet Y., Geraud G., Hosford D., Braquet P. (1991) Superoxide dismutase (SOD) and the PAF antagonist (BN 52021) reduce small intestinal damage induced by ischemia-reperfusion. Free Radic Res Commun 12, 725–735. 10.3109/10715769109145852 CASPubMedWeb of Science®Google Scholar 4 Hoelscher M., Klaess G., Kallerhoff M., Bretschneider HJ (1984) Is Euro collins solution losing its protective ability above 15 oC Transplant Proc 16, 166–171. CASWeb of Science®Google Scholar 5 Lopez Farre A., Torralbo M., Lopez Novoa JM (1988) Glomeruli from ischemic rat kidneys produce increased amounts of platelet activating factor. Biochem Biophys Res Commun 152, 129–135. 10.1016/S0006-291X(88)80689-2 CASPubMedWeb of Science®Google Scholar 6 Lopez Farre A., Bernabeu F., Gomez Garre D., Ramon y Cajal S., Braquet P., Lopez Novoa JM (1990) Platelet activating factor antagonist treatment protects against postischemic acute renal failure in rats. J Pharmacol Exp Ther 253, 328–333. CASPubMedWeb of Science®Google Scholar 7 Lopez Farre A., Gomez Garre D., Bernabeu F., Montanes I., Millas I., Lopez Novoa J. (1991) Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF. Kidney Int 39, 624–630. 10.1038/ki.1991.74 CASPubMedWeb of Science®Google Scholar 8 Pirotzky E., Bidault J., Burtin C., Gubler MC, Benveniste J. (1984) Release of platelet activating factor, slow reacting substance and vasoactive amines from isolated rat kidneys. Kidney Int 25, 404–411. 10.1038/ki.1984.31 CASPubMedWeb of Science®Google Scholar 9 Santos JC, Sanz E., Caramelo C., Hernando L., Lopez Novoa JM (1985) Effect of PAF-acether on renal function in dogs. Kidney Int 28, 587. Web of Science®Google Scholar 10 Santos OFP, Boim MA, Bregman R., Draibe SA, Barros EJC, Pirotzky E., Schor N., Braquet P. (1989) Effect of platelet activating factor antagonist on cyclosporine nephrotoxicity: glomerular hemodynamics evaluation. Transplantation 47, 592–595. 10.1097/00007890-198904000-00005 PubMedWeb of Science®Google Scholar 11 Santos OFP, Boim MA, Barros EJG, Schor N. (1991) Role of platelet activating factor in gentamicin and cisplatin nephrotoxicity. Kidney Int 40, 742–747. 10.1038/ki.1991.269 PubMedWeb of Science®Google Scholar 12 Torras J., Bordalba JR, Seron D., Carrera M., Castelao AM, Poveda R., Alsina J., Griño JM (1992) An experimental comparison between isotonic saline solution, Eurocollins and a flush solution with mannitol in the prevention of renal damage due to warm ischemia. Transplant Proc 24, 54–55. CASPubMedWeb of Science®Google Scholar Citing Literature Volume6, Issue4July 1993Pages 236-238 ReferencesRelatedInformation
Referência(s)